CD8A and acute lymphoblastic leukemia: In an experimental study, Sabatino S. et al. genetically engineered and generated CD19-CAR-modified CD8+ Tscm and demonstrated that when compared to CD8+ CAR T cells generated by current clinical protocols, CD19-CAR-modified CD8+ Tscm exhibited enhanced metabolic fitness and longer lasting antitumor effects against ALL xenografts [70].